Sign In
Buy KALV
$26.95
+0.0100 (+0.0371%)
At Close: Jun 03, 2026
Here's Why You Can Add KalVista (KALV) Stock to Your Portfolio
12:09pm, Wednesday, 12'th Apr 2023
Here we discuss some reasons why investing in KalVista Pharmaceuticals (KALV) stock now is a good idea.
KalVista Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference
06:30am, Wednesday, 12'th Apr 2023
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm
Wall Street Analysts Think KalVista Pharmaceuticals, Inc. (KALV) Could Surge 145.98%: Read This Before Placing a Bet
11:24am, Tuesday, 04'th Apr 2023
The consensus price target hints at a 146% upside potential for KalVista Pharmaceuticals, Inc. (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend
KalVista Pharmaceuticals, Inc. (KALV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
11:29am, Wednesday, 22'nd Mar 2023
KalVista Pharmaceuticals, Inc. (KALV) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate rev
KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology
06:30am, Thursday, 16'th Feb 2023
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm
What Makes KalVista Pharmaceuticals, Inc. (KALV) a New Buy Stock
01:33pm, Tuesday, 07'th Feb 2023
KalVista Pharmaceuticals, Inc. (KALV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term
Wall Street Analysts Think KalVista Pharmaceuticals, Inc. (KALV) Could Surge 149.94%: Read This Before Placing a Bet
11:18am, Tuesday, 07'th Feb 2023
The mean of analysts' price targets for KalVista Pharmaceuticals, Inc. (KALV) points to a 149.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong
KalVista Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
06:30am, Friday, 03'rd Feb 2023
CAMBRIDGE, Mass. & SALISBURY, England--( BUSINESS WIRE )--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializ
KalVista Pharmaceuticals: The Share Price Rally Requires An Adjustment Of My Investment Thesis
08:30am, Wednesday, 25'th Jan 2023
KalVista intends to provide best-in-class therapies, both for acute on-demand and prophylaxis treatment, to fundamentally change the way HAE is treated. The backbone of the company is Sebetralstat, wh
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
06:45am, Monday, 07'th Nov 2022
CAMBRIDGE, Mass.
KalVista: Another Setback But The Key Value Driver Is Still In Place
11:42am, Friday, 14'th Oct 2022
KalVista intends to provide best-in-class therapies, both for acute on-demand and prophylaxis treatment, to fundamentally change the way HAE is treated. Its lead drug Sebetralstat is currently being i
KalVista (KALV) Stock Continues to Decline: Here's Why
03:03pm, Thursday, 06'th Oct 2022
The recent setback faced by KalVista (KALV) for terminating the phase II KOMPLETE study evaluating KVD824 for prophylactic treatment of hereditary angioedema hurts the stock.
Why Is KalVista Pharmaceuticals (KALV) Stock Down 50% Today?
11:41am, Tuesday, 04'th Oct 2022
KalVista Pharmaceuticals (NASDAQ: KALV ) is trending on popular financial social media right now, but it's not good news. Reportedly, there were safety-related concerns over KalVista's clinical study
KalVista shares slide 26% premarket after company halts trial of treatment for hereditary angioedema
06:45am, Tuesday, 04'th Oct 2022
KalVista Pharmaceuticals Inc. shares KALV, -1.86% tumbled 26% in premarket trade Tuesday, after the company said it's halting a Phase 2 trial of a treatment for hereditary angioedema, after multiple p
KalVista Pharmaceuticals to Present at the 2022 HAEi Global Leadership Workshop
06:45am, Friday, 30'th Sep 2022
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and comm
